2024-12-01 2025-11-30 2025-11-30 false 10725303 SNK Eyecare Ltd 47782Retail sale by opticians iso4217:GBP xbrli:pure 107253032024-12-01 107253032025-11-30 107253032024-12-01 2025-11-30 10725303bus:SmallEntities2024-12-01 2025-11-30 10725303bus:AuditExempt-NoAccountantsReport2024-12-01 2025-11-30 10725303bus:FullAccounts2024-12-01 2025-11-30 10725303core:WithinOneYear2025-11-30 10725303core:AfterOneYear2025-11-30 10725303core:WithinOneYear2024-12-01 2025-11-30 10725303core:AfterOneYear2024-12-01 2025-11-30 10725303core:CurrentFinancialInstruments2025-11-30 10725303core:Non-currentFinancialInstruments2025-11-30 10725303core:CurrentFinancialInstruments2024-12-01 2025-11-30 10725303core:Non-currentFinancialInstruments2024-12-01 2025-11-30 10725303core:LandBuildings2024-12-01 2025-11-30 10725303core:FurnitureFittings2024-12-01 2025-11-30 10725303core:OfficeEquipment2024-12-01 2025-11-30 10725303core:Vehicles2024-12-01 2025-11-30 10725303core:PlantMachinery2024-12-01 2025-11-30 10725303core:OtherPropertyPlantEquipment2024-12-01 2025-11-30 10725303core:LandBuildings2025-11-30 10725303core:PlantMachinery2025-11-30 10725303core:Vehicles2025-11-30 10725303core:FurnitureFittings2025-11-30 10725303core:OfficeEquipment2025-11-30 10725303core:OtherPropertyPlantEquipment2025-11-30 10725303core:Right-of-useAssets2024-12-01 2025-11-30 10725303core:Right-of-useAssets2025-11-30 10725303core:Goodwill2024-12-01 2025-11-30 10725303core:PatentsTrademarksLicencesConcessionsSimilar2024-12-01 2025-11-30 10725303core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-01 2025-11-30 10725303core:OtherResidualIntangibleAssets2024-12-01 2025-11-30 10725303core:Goodwill2025-11-30 10725303core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-11-30 10725303core:PatentsTrademarksLicencesConcessionsSimilar2025-11-30 10725303core:OtherResidualIntangibleAssets2025-11-30 10725303dpl:CostSales2024-12-01 2025-11-30 10725303dpl:AdministrativeExpenses2024-12-01 2025-11-30 10725303dpl:DistributionCosts2024-12-01 2025-11-3010725303core:ShareCapital2025-11-30 10725303core:SharePremium2025-11-30 10725303core:RevaluationReserve2025-11-30 10725303core:OtherReservesSubtotal2025-11-30 10725303core:ShareCapitalPreferenceShares2025-11-30 10725303core:CapitalRedemptionReserve2025-11-30 10725303core:OtherCapitalReserve2025-11-30 10725303core:RetainedEarningsAccumulatedLosses2025-11-3010725303core:ShareCapital2024-12-01 2025-11-30 10725303core:SharePremium2024-12-01 2025-11-30 10725303core:RevaluationReserve2024-12-01 2025-11-30 10725303core:OtherReservesSubtotal2024-12-01 2025-11-30 10725303core:RetainedEarningsAccumulatedLosses2024-12-01 2025-11-301072530312024-12-01 2025-11-30 1072530322024-12-01 2025-11-3010725303core:ShareCapital12024-12-01 2025-11-30 10725303core:ShareCapital22024-12-01 2025-11-3010725303core:SharePremium12024-12-01 2025-11-30 10725303core:SharePremium22024-12-01 2025-11-3010725303core:RevaluationReserve12024-12-01 2025-11-30 10725303core:RevaluationReserve22024-12-01 2025-11-3010725303core:RetainedEarningsAccumulatedLosses12024-12-01 2025-11-30 10725303core:RetainedEarningsAccumulatedLosses22024-12-01 2025-11-301072530312024-12-01 2025-11-3010725303core:Non-currentFinancialInstrumentscore:CostValuation2024-12-01 10725303core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:CostValuation2025-11-3010725303core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2024-12-01 10725303core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-11-30 10725303core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-11-30 10725303core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-11-3010725303core:Non-currentFinancialInstruments2025-11-30 10725303core:Non-currentFinancialInstruments2024-11-30107253032023-12-01 107253032024-11-30 107253032023-12-01 2024-11-30 10725303core:WithinOneYear2024-11-30 10725303core:AfterOneYear2024-11-30 10725303core:CurrentFinancialInstruments2024-11-30 10725303core:Non-currentFinancialInstruments2024-11-30 10725303core:LandBuildings2024-11-30 10725303core:PlantMachinery2024-11-30 10725303core:Vehicles2024-11-30 10725303core:FurnitureFittings2024-11-30 10725303core:OfficeEquipment2024-11-30 10725303core:OtherPropertyPlantEquipment2024-11-30 10725303core:Right-of-useAssets2024-11-30 10725303core:Goodwill2024-11-30 10725303core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-30 10725303core:PatentsTrademarksLicencesConcessionsSimilar2024-11-30 10725303core:OtherResidualIntangibleAssets2024-11-30 10725303dpl:AdministrativeExpenses2023-12-01 2024-11-3010725303core:ShareCapital2024-11-30 10725303core:SharePremium2024-11-30 10725303core:RevaluationReserve2024-11-30 10725303core:OtherReservesSubtotal2024-11-30 10725303core:ShareCapitalPreferenceShares2024-11-30 10725303core:CapitalRedemptionReserve2024-11-30 10725303core:OtherCapitalReserve2024-11-30 10725303core:RetainedEarningsAccumulatedLosses2024-11-3010725303core:RetainedEarningsAccumulatedLosses2023-12-01 10725303core:ShareCapital2023-12-01 10725303core:SharePremium2023-12-01 10725303core:RevaluationReserve2023-12-01 10725303core:ShareCapital2023-12-01 2024-11-30 10725303core:SharePremium2023-12-01 2024-11-30 10725303core:RevaluationReserve2023-12-01 2024-11-30 10725303core:OtherReservesSubtotal2023-12-01 2024-11-30 10725303core:RetainedEarningsAccumulatedLosses2023-12-01 2024-11-301072530312023-12-01 2024-11-30 1072530322023-12-01 2024-11-3010725303core:ShareCapital12023-12-01 2024-11-30 10725303core:ShareCapital22023-12-01 2024-11-3010725303core:SharePremium12023-12-01 2024-11-30 10725303core:SharePremium22023-12-01 2024-11-3010725303core:RevaluationReserve12023-12-01 2024-11-30 10725303core:RevaluationReserve22023-12-01 2024-11-3010725303core:RetainedEarningsAccumulatedLosses12023-12-01 2024-11-30 10725303core:RetainedEarningsAccumulatedLosses22023-12-01 2024-11-3010725303bus:Director12024-12-01 2025-11-3010725303bus:Director22024-12-01 2025-11-3010725303bus:PrivateLimitedCompanyLtd2024-12-01 2025-11-30
SNK Eyecare Ltd
Unaudited Financial Statements
for the year ended 30 November 2025
Company registration number 10725303
(England and Wales)

Company Information

For the year ended 30 November 2025
Directors Khorugdharry, Shamila
Patel, Kalpesh

Registered office 15 Canterbury Road Canterbury Road
Sittingbourne
ME10 4SG

Registered number 10725303

Accountant Churchmill Partnership Ltd
Brook House
Mint Street
Godalming
Surrey
GU7 1HE

Balance Sheet

As at 30 November 2025
Notes
2025
2024
£
£
£
£
Fixed assets
Intangible assets
4
94,408
107,895
Tangible assets
5
41,145
54,538
135,553
162,433
Current assets
Stocks
6
32,257
39,638
Debtors
7
43,160
36,552
Cash at bank and in hand
16,301
49,999
91,718
126,189
Creditors
Amounts falling due within one year
8
(113,241)
(125,046)
(113,241)
(125,046)
Net current assets (liabilities)
(21,523)
1,143
Total assets less current liabilities
114,030
163,576
Creditors
Amounts falling due after one year
9
(100,252)
(137,825)
(100,252)
(137,825)
Provisions for liabilities
10
(7,817)
(13,206)
Net assets (liabilities)
5,961
12,545
Capital and reserves
Called up share capital
10
10
Profit and loss account
5,951
12,535
Total equity
5,961
12,545

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 26 August 2026 and are signed on its behalf by:

Khorugdharry, Shamila
Khorugdharry, Shamila
Director

Company registration number 10725303

Notes to the Financial Statements

For the year ended 30 November 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.



2.3. Pensions

Defined contribution pension plan

The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.

2.4. Current taxation

Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income.


Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.

2.5. Deferred tax

Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

2.6. Intangible assets and amortisation

Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.

Goodwill

Goodwill arising on an acquisition of a business is carried at cost less accumulated impairment losses, if any. Goodwill is amortised over its expected useful life which is estimated to be fifteen years. Goodwill is assessed for impairment when there are indicators of impairment and any impairment is charged to the income statement. No reversals of impairment are recognised.

2.7. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Plant and machinery
10
Straight-line
Office and computer equipment
25
Straight-line

2.8. Stocks and work in progress

Inventories are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, inventories are assessed for impairment. If an item of inventory is impaired, the carrying amount is reduced to its selling price less costs to complete and sell, and the impairment loss is recognised immediately in the income statement. When inventories are sold, the carrying amount is recognised as an expense in the period in which the related revenue is recognised.



3. Employees

The average number of employees during the year was 5 (2024: 6).

4. Intangible assets

Goodwill
Total
£
£
Cost
At 1 December 2024
202,302
202,302
At 30 November 2025
202,302
202,302
Amortisation and impairment
At 1 December 2024
94,407
94,407
Charge for the period
13,487
13,487
At 30 November 2025
107,894
107,894
Net book value
At 30 November 2025
94,408
94,408
At 30 November 2024
107,895
107,895

5. Tangible fixed assets

Plant and machinery
Fixtures and fittings
Office equipment
Total
£
£
£
£
Cost
At 1 December 2024
108,593
45,044
44,262
197,899
Additions
685
-
46
731
At 30 November 2025
109,278
45,044
44,308
198,630
Depreciation and impairment
At 1 December 2024
72,891
26,911
43,559
143,361
Charge for the period
9,096
4,504
524
14,124
At 30 November 2025
81,987
31,415
44,083
157,485
Net book value
At 30 November 2025
27,291
13,629
225
41,145
At 30 November 2024
35,702
18,133
703
54,538

6. Stocks and work in progress

2025
2024
£
£
Finished goods
32,257
39,638
Total
32,257
39,638

7. Debtors

2025
2024
£
£
Trade debtors
29,744
22,973
Other debtors
13,416
13,579
Total due within one year
43,160
36,552
Total due after one year
-
-
Total
43,160
36,552

8. Creditors due within one year

2025
2024
£
£
Bank loans and overdrafts
51,969
48,665
Trade creditors
44,297
50,505
Other creditors
3,573
3,569
Directors loan account
2,952
4,670
Taxation and social security
8,080
15,357
Accruals and deferred income
2,370
2,280
Total
113,241
125,046

9. Creditors due after one year

2025
2024
£
£
Bank loans and overdrafts
100,252
137,825
Total
100,252
137,825

10. Provisions for liabilities

2025
2024
£
£
Deferred tax
7,817
13,206
Total
7,817
13,206